Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1953 1
1957 1
1971 1
1981 1
1982 1
1983 1
1992 1
1993 1
1995 1
1996 2
1997 2
1998 1
2000 2
2001 2
2002 2
2003 2
2004 2
2005 7
2006 3
2007 4
2008 2
2009 2
2010 8
2011 7
2012 3
2013 6
2014 6
2015 6
2016 6
2017 8
2018 14
2019 10
2020 28
2021 31
2022 24
2023 23
2024 14
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: fay k. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
In Reply.
Fay KE, Bartz D. Fay KE, et al. Obstet Gynecol. 2023 Feb 1;141(2):420. doi: 10.1097/AOG.0000000000005065. Obstet Gynecol. 2023. PMID: 36657147 No abstract available.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Bartlett NL, et al. Among authors: fay k. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. Blood Adv. 2023. PMID: 37067952 Free PMC article.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE. Sehn LH, et al. Among authors: fay k. Blood. 2025 Feb 13;145(7):708-719. doi: 10.1182/blood.2024025454. Blood. 2025. PMID: 39447094 Free PMC article. Clinical Trial.
Toxicities of herbal abortifacients.
Feng C, Fay KE, Burns MM. Feng C, et al. Among authors: fay ke. Am J Emerg Med. 2023 Jun;68:42-46. doi: 10.1016/j.ajem.2023.03.005. Epub 2023 Mar 7. Am J Emerg Med. 2023. PMID: 36924751 Free PMC article. Review.
The intestinal microenvironment in sepsis.
Fay KT, Ford ML, Coopersmith CM. Fay KT, et al. Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt B):2574-2583. doi: 10.1016/j.bbadis.2017.03.005. Epub 2017 Mar 7. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 28286161 Free PMC article. Review.
Reproductive Coercion and Women's Health.
Fay K, Yee L. Fay K, et al. J Midwifery Womens Health. 2018 Sep-Oct;63(5):518-525. doi: 10.1111/jmwh.12885. Epub 2018 Aug 13. J Midwifery Womens Health. 2018. PMID: 30102016 Review.
An Ecological Model of Reproductive Coercion.
Warling A, Treder KM, Brandi K, Kumar B, Fay KE. Warling A, et al. Among authors: fay ke. J Midwifery Womens Health. 2023 Nov-Dec;68(6):697-701. doi: 10.1111/jmwh.13555. Epub 2023 Aug 2. J Midwifery Womens Health. 2023. PMID: 37531176 Free PMC article. No abstract available.
204 results